当前位置: X-MOL 学术JAMA Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dual Checkpoint Inhibition in Melanoma With ≥1% PD-L1—Time to Reassess the Evidence
JAMA Oncology ( IF 22.5 ) Pub Date : 2024-05-16 , DOI: 10.1001/jamaoncol.2024.1117
Marco Donia 1 , Vinay Prasad 2
Affiliation  

This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy.

中文翻译:


PD-L1 ≥1% 的黑色素瘤的双重检查点抑制——是时候重新评估证据了



本观点讨论使用抗 PD-1 单一疗法作为 PD-L1 染色阳性的初治转移性黑色素瘤患者的主要治疗选择,而不是双检查点抑制疗法。
更新日期:2024-05-16
down
wechat
bug